Firefly Progresses Toward Development and Commercial Launch of its Foundation Model of the Human Brain Powered by NVIDIA GPU Acceleration
MWN-AI** Summary
Firefly Neuroscience, Inc. (NASDAQ: AIFF) has made significant strides in its mission to enhance brain health outcomes for individuals with neurological and mental disorders. As of March 4, 2026, the company reported a remarkable 20-fold expansion in its commercial footprint and a staggering 33-fold increase in EEG/ERP brain scan volumes. This expansion follows Firefly's acquisition of Evoke Neuroscience and the successful implementation of key growth initiatives, leading to partnerships with 99 commercial users, culminating in over 10,800 brain scan assessments.
The extraordinary growth percentages—1,880% for partner sites and an impressive 3,227% for EEG/ERP clinical assessments—highlight Firefly’s successful execution of its strategic goals. CEO Greg Lipschitz emphasized the role of AI and advanced EEG/ERP technology in the company's mission to transform neuroscience. Leveraging NVIDIA L40S GPU acceleration for EEG/ERP processing, Firefly aims to capitalize on its rapidly growing dataset of over 191,000 brain scans to drive new discoveries in cognitive biomarkers. This initiative positions Firefly to achieve the ambitious goal of launching the world’s first EEG/ERP-based foundation model of the human brain.
Firefly's innovative, AI-driven brain analytics technology has already gained FDA-510(k) clearance, with a strong potential to revolutionize diagnostics and treatment monitoring across various conditions, including depression, dementia, anxiety disorders, concussions, and ADHD. As Firefly continues to grow and innovate, the company remains committed to harnessing cutting-edge technology to improve brain health outcomes, signaling a promising future within the neurotechnology sector. For further details, visit Firefly’s website at www.fireflyneuro.com.
MWN-AI** Analysis
Firefly Neuroscience, Inc. (NASDAQ: AIFF) has made significant strides in its mission to revolutionize brain health outcomes with its foundation model of the human brain powered by NVIDIA GPU acceleration. The recent announcement of a 20-fold expansion of its commercial footprint and a staggering 33-fold increase in EEG/ERP scan volumes positions Firefly as a frontrunner in the rapidly evolving field of AI-driven neuroscience.
The acquisition of Evoke Neuroscience has substantially enhanced Firefly's capabilities, enabling it to engage with 99 commercial partners and conduct over 10,800 brain scans, illustrating a robust growth trajectory. This momentum not only solidifies Firefly's market presence but also amplifies its access to valuable data, essential for advancing cognitive brain biomarker discovery.
Investors should consider Firefly's unique positioning in the market, particularly its proprietary database of over 191,000 EEG/ERP scans, which stands as the largest of its kind. This substantial data repository enables the company to leverage AI technologies effectively, potentially transforming diagnostic and treatment monitoring methodologies for various neurological conditions.
However, the path ahead is not devoid of challenges. Firefly’s ambitious growth plan entails inherent risks and uncertainties associated with technological advancements and regulatory approvals. As such, investors should remain cognizant of these factors while assessing potential rewards.
With the increasing demand for innovative solutions in mental health care and neurological treatment, Firefly’s ambitious targets align well with market needs. Forward-thinking investors may view the company as a compelling opportunity, particularly as it continues to expand its clinical capabilities and leverage cutting-edge technology.
In conclusion, while the current momentum appears promising, careful monitoring of operational execution and market trends is advisable for those considering an investment in Firefly Neuroscience.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Company reports 20-fold expansion of commercial footprint, 33-fold increase in EEG/ERP brain scan volumes -
- Harnessing increased data and cutting-edge supercomputing potentially unlocks new AI-driven biomarker discovery capabilities and significantly advances Firefly on its path of building a foundation model of the human brain -
KENMORE, N.Y., March 04, 2026 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, is pleased to announce a greater than 20-fold expansion of its commercial footprint, and a 33-fold Increase in its EEG/ERP scan volumes.
Through its acquisition of Evoke Neuroscience, Inc. and the successful execution of its key internal growth initiatives, Firefly ended 2025 partnered with 99 commercial users who completed a total of more than 10,800 EEG/ERP brain scans.
The year-over-year increases in partner sites and EEG/ERP clinical assessments represent growth of 1,880% and 3,227%, respectively, since the end of 2024.
“As demonstrated by this significant expansion of our commercial footprint and meaningful increase in our brain scan volumes, we continue to successfully execute against the key pillars of our growth strategy,” said Greg Lipschitz, Firefly’s Chief Executive Officer. “Our mission is to harness the power of AI and EEG/ERP to transform neuroscience and clinical development. With an exponentially growing foundation of clean data, and by deploying NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing, the Company believes that it is poised to make additional new breakthroughs in cognitive brain biomarker discovery, and to fulfill its goal of building and launching the world’s first EEG/ERP-based foundation model of the human brain.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions designed to provide clinicians and researchers with unparalleled insights into brain function. Firefly’s proprietary database currently consists of over 191,000 EEG/ERP brain scans, making it the world’s largest known standardized EEG/ERP repository. Firefly’s EEG-based, AI-driven, and FDA-510(k)-cleared brain analytics technology has the potential to revolutionize diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD.
Please visit www.fireflyneuro.com for more information.
Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management team’s expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) and other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, those factors described under the heading “Risk Factors” in the reports and other filings of Firefly with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor & Media Contact
Stephen Kilmer
(646) 274-3580
stephen.kilmer@fireflyneuro.com
FAQ**
How does Firefly Neuroscience Inc. AIFF plan to leverage its 20-fold expansion of commercial footprint to enhance partnerships and increase EEG/ERP brain scan volumes further in the coming years?
What strategies is Firefly Neuroscience Inc. AIFF employing to ensure the quality and integrity of the data collected from its growing EEG/ERP brain scan repository?
Can you provide more details on how Firefly Neuroscience Inc. AIFF intends to utilize NVIDIA L40S GPU acceleration to power next-generation EEG/ERP processing and biomarker discovery?
Given the significant year-over-year growth, what specific risks or challenges does Firefly Neuroscience Inc. AIFF foresee that could impact its ambitious plans for developing an EEG/ERP-based foundation model of the human brain?
**MWN-AI FAQ is based on asking OpenAI questions about Firefly Neuroscience Inc. (NASDAQ: AIFF).
NASDAQ: AIFF
AIFF Trading
49.06% G/L:
$1.9899 Last:
33,599,140 Volume:
$1.645 Open:
